Lugano, Switzerland, 23 February 2022 – The ESMO Targeted Anticancer Therapies Congress 2022, designed for basic scientists, physicians and translational researchers belonging to academic settings, industry and regulatory agencies will be held as a virtual meeting.
The scientific programme will provide new data and insightful presentations in the area of drug discovery and development for a broad range of targets, precision medicine and early clinical trial methodology.
Programme highlights
- The role of COVID-19 vaccination to bring early phase anticancer drug development back to normal
- Targeting resistance to immunotherapy and new immune pathways to optimise immunotherapy efficacy in NSCLC
- The personalisation of antibody-drug conjugates (ADC) as the future of therapeutic strategies
- Breakthrough research combining ctDNA and computational biology to uncover new vulnerabilities of cancer
- T-cells, CAR-T cells and beyond:
- Redirecting T-cells to kill cancer cells
- The use of biospecific gamma-delta T-cells engagers to treat cancer
- T-cell receptor (TCRs)-based approaches to target solid tumours
- NK cells as effectors of tumour control
- Molecular imaging of immune checkpoints, immune cells and CAR-T cells for profiling tumour heterogeneity and selecting immunotherapy
- Next generation genome editing for enabling allogeneic cell products
- New developments in tumour infiltrating lymphocyte (TIL) therapy
Keynote lectures
- “The power of collaboration” by Lesley K. Seymour, TAT 2022 Honorary Award Laureate, Monday 7 March at 12:25 on Channel 1.
Prof. Seymour will be presented with the TAT2022 Honorary Award in recognition of her outstanding contributions to early drug development and innovative clinical trial methodology. - “Current clinical, molecular and immunological landscapes of breast cancer and future directions” by Fabrice André, Tuesday 8 March at 13:00 on Channel 1.
Media registration
ESMO welcomes media interested in reporting from ESMO events and on cancer issues. Only through the official accreditation process with the ESMO Media Registration Form, accredited media representatives will be able to access scientific and educational sessions (live streamed and on-demand), live chat and Q&A, e-posters, virtual exhibition and industry satellite symposia, Congress webcasts.
Further information
ESMO Press Office
press@esmo.org
-END-
Notes to Editors
Please make sure to use the official name of the meeting in your reports: ESMO Targeted Anticancer Therapies Virtual Congress 2022
Official Congress Hashtag: #ESMOTAT22
About the European Society for Medical Oncology (ESMO)
ESMO is the leading professional organisation for medical oncology. With more than 25,000 members representing oncology professionals from over 160 countries worldwide, ESMO is the society of reference for oncology education and information. Driven by a shared determination to secure the best possible outcomes for patients, ESMO is committed to standing by those who care about cancer through addressing the diverse needs of #ONEoncologycommunity, offering #educationforLIFE, and advocating for #accessiblecancerCARE. Visit www.esmo.org